Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Dyadic Reports Third Quarter 2019 Results And  Recent Developments
BiotechnologyEarnings

Dyadic Reports Third Quarter 2019 Results And Recent Developments

November 13, 2019 4:00 PM

New Fully Funded Research Collaboration with Leading Animal Health Company; Fifth Partnership in Animal Sector Expansion of Existing Research Collaboration to Express an Additional Protein with Major Animal Health Company New Fully Funded Research Collaboration to Express Proteins with Top Tier Pharmaceutical Company Continued Progress with Existing Scientific Partners Joined Russell Microcap® Index JUPITER, FL / ACCESSWIRE / November 13, 2019 /...

Read more
Cantabio Announces Publication of Novel Study Demonstrating the Importance of the DJ-1 Protein in the Onset and Pathology of Alzheimer's and Parkinson's disease
BiotechnologyCompany Update

Cantabio Announces Publication of Novel Study Demonstrating the Importance of the DJ-1 Protein in the Onset and Pathology of Alzheimer's and Parkinson's disease

November 13, 2019 8:30 AM

Study shows that DJ-1 misfolds to form b-sheet structured fibrillar aggregates that co-localize with pathological amyloid deposits characteristic of Parkinson's and Alzheimer's disease in patients' post-mortem brain tissues PALO ALTO, CA / ACCESSWIRE / November 13, 2019 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease modifying therapeutics for Alzheimer's (AD),...

Read more
Frelii Announces Master License Agreement with Systemic Formulations
BiotechnologyCompany Update

Frelii Announces Master License Agreement with Systemic Formulations

November 12, 2019 9:00 AM

LEHI, UTAH / ACCESSWIRE / November 12, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or the "Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today it has signed a Master License Agreement ("Agreement) with Systemic Formulations Inc. ("Customer"). "We believe the efficacy of our genome discovery artificial intelligence, Navii, has been further...

Read more
Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
BiotechnologyCompany Update

Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

November 11, 2019 7:00 AM

Company to Host an Investor Conference Call On Monday, November 11, 2019 At 8:00 AM EST BOSTON, MA / ACCESSWIRE / November 11, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today reported its financial results for the third quarter of 2019 ended September...

Read more
Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
BiotechnologyCompany Update

Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

November 9, 2019 12:00 PM

BOSTON, MA / ACCESSWIRE / November 9, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the presentation of data from the phase 1 dose-escalation monotherapy study of PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors,...

Read more
ReShape Lifesciences to Host Third Quarter 2019 Conference Call on November 14, 2019
BiotechnologyConference Call

ReShape Lifesciences to Host Third Quarter 2019 Conference Call on November 14, 2019

November 7, 2019 5:30 PM

SAN CLEMENTE, CA / ACCESSWIRE / November 7, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today announced that it will host a conference call to discuss financial results for the third quarter of 2019 on Thursday, November 14, 2019 at 1:30 PM Pacific Time. Individuals interested in listening to the conference call may do so by...

Read more
GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update
BiotechnologyEarnings

GeoVax Reports 2019 Third Quarter Financial Results and Provides Corporate Update

November 7, 2019 2:05 PM

The Underlying Value of GeoVax, and the Promise of the Technology...A Comprehensive Review of GeoVax's Various Development Programs ATLANTA, GA / ACCESSWIRE / November 7, 2019 / GeoVax Labs, Inc. (OTCQB:GOVX), a biotechnology company developing human immunotherapies and vaccines, today announced its financial results for the quarter ended September 30, 2019 and provided an update on its corporate development progress. View full release,...

Read more
Pieris Pharmaceuticals to Host R&D Event
BiotechnologyCompany Update

Pieris Pharmaceuticals to Host R&D Event

November 7, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 7, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that the Company will host an R&D event in New York on Tuesday, November 19, 2019 from 12:00 - 3:30 PM EST. The R&D event will feature presentations from...

Read more
InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa
BiotechnologyCompany Update

InflaRx Reports Positive Results from the Open Label Extension Part of the SHINE Study for IFX-1 in Hidradenitis Suppurativa

November 7, 2019 2:10 AM

70.6% of week 16 HiSCR responders maintain response throughout week 40 while 41.8% of non-responders become responders (total HiSCR rate = 56.3% at end of treatment) 78.2% of OLE patients complete extension period and show marked reduction in all inflammatory lesions IFX-1 long-term treatment well tolerated, no drug-related serious adverse events Conference call to provide details and corporate strategic update scheduled for 7 November...

Read more
Calmare Therapeutics Has $842,000 Judgment Vacated by the U.S. Court Of Appeals for the Second Circuit
BiotechnologyCompany Update

Calmare Therapeutics Has $842,000 Judgment Vacated by the U.S. Court Of Appeals for the Second Circuit

November 6, 2019 10:30 AM

FAIRFIELD, CT / ACCESSWIRE / November 6, 2019 / Calmare Therapeutics Incorporated, (OTC PINK:CTTC) ("CTI"), the pain mitigation company ("Calmare"), has $841,673.85 judgment vacated by the United States Court of Appeals for the Second Circuit (the "Court"). On September 29, 2017, the District Court of Connecticut entered a final judgment awarding GEOMC Co. Ltd. - a South Korea corporation - attorneys' fees in the amount of $836,442.05 and...

Read more
Cofactor Genomics Opens Early Access to New T Cell Exhaustion Models through Predictive Immune Modeling Platform
BiotechnologyCompany Update

Cofactor Genomics Opens Early Access to New T Cell Exhaustion Models through Predictive Immune Modeling Platform

November 6, 2019 8:01 AM

-- Announces "Functional to FFPE" Early-Access Grant Program -- SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2019 / Cofactor Genomics, leaders in RNA-based technologies and diagnostics, announced today they will provide early access to a new feature in their Predictive Immune Modeling platform which enables cell-state characterization within FFPE tissue samples. Measuring cell-states, such as T cell exhaustion, has been cited as integral to...

Read more
Leading Denver-Based Orthopedic Surgeon to Join Vitro Biopharma's Scientific Advisory Board
BiotechnologyCompany UpdateManagement Changes

Leading Denver-Based Orthopedic Surgeon to Join Vitro Biopharma's Scientific Advisory Board

November 5, 2019 12:35 PM

GOLDEN, CO / ACCESSWIRE / November 5, 2019 / Vitro Diagnostics, Inc. (OTCPK:VODG), dba Vitro Biopharma announced the appointment of Dr. In Sok Yi MD to its Scientific Advisory Board (SAB). Dr Yi is board certified in Orthopedic Surgery and Surgery of the Hand. He presently practices with Peak Orthopedics and Spine in Englewood Colorado. Dr Yi has a strong background in academic medicine and clinical practice. Following his medical training,...

Read more
Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
BiotechnologyCompany Update

Pieris Pharmaceuticals to Present Phase 1 Data for 4-1BB/HER2 Bispecific PRS-343 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

November 5, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 5, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that the Company will present phase 1 dose-escalation monotherapy data for PRS-343, a 4-1BB/HER2 bispecific for the treatment of HER2-positive solid tumors, in a...

Read more
Edesa Biotech Announces Upcoming Conference Schedule
BiotechnologyCompany UpdateConferences

Edesa Biotech Announces Upcoming Conference Schedule

November 5, 2019 7:30 AM

TORONTO, ON / ACCESSWIRE / November 5, 2019 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that its management will present at the H.C. Wainwright 5th Annual Israel Conference in Tel Aviv, Israel. The company is scheduled to participate in a panel discussion related to initial public offerings and reverse acquisitions on November 10, 2019 at 1:00 pm (IST) at the Hilton Tel Aviv hotel. Edesa...

Read more
Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in
BiotechnologyCompany Update

Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in

November 4, 2019 8:00 AM

BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it has entered into a securities purchase agreement with existing and new institutional investors to raise $32 million. The private placement was led by...

Read more
Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019
BiotechnologyCompany Update

Pieris Pharmaceuticals to Host Third Quarter 2019 Investor Call and Corporate Update on November 11, 2019

November 4, 2019 7:00 AM

BOSTON, MA / ACCESSWIRE / November 4, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a third quarter 2019 investor call on Monday, November 11, 2019 at 8:00 AM EST to discuss financial results and provide a corporate...

Read more
INTERIM MANAGEMENT STATEMENT - Q3 2019: Encouraging Additional Phase 3 Data Presented for Abicipar, and Start of Phase 1 Trial for MP0310, the First Immuno-oncology DARPin(R) with a Novel Therapeutic Design
BiotechnologyCompany UpdateInvestor Relations

INTERIM MANAGEMENT STATEMENT - Q3 2019: Encouraging Additional Phase 3 Data Presented for Abicipar, and Start of Phase 1 Trial for MP0310, the First Immuno-oncology DARPin(R) with a Novel Therapeutic Design

October 31, 2019 2:00 AM

Research & Development: MP0310 (FAP x 4-1BB): First patient dosed in phase 1 trial for this tumor-localized immune-modulator, representing a key milestone as the first novel therapeutic design of an immuno-oncology DARPin® candidate in clincial development (in co-development with Amgen) MP0250 (VEGF x HGF) in Multiple Myeloma: Update on ongoing phase 2 PI trial (in combination with Velcade®) to be provided at ASH and company's R&D Day in...

Read more
Dyadic to Report Third Quarter 2019 Financial Results on Wednesday November 13, 2019
BiotechnologyConference CallEarnings

Dyadic to Report Third Quarter 2019 Financial Results on Wednesday November 13, 2019

October 30, 2019 4:30 PM

JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results...

Read more
Frelii Announces Shareholder Update
BiotechnologyCompany Update

Frelii Announces Shareholder Update

October 30, 2019 9:00 AM

LEHI, UT / ACCESSWIRE / October 30, 2019 / Frelii, Inc. (OTC PINK:FRLI) ("Frelii" or "the Company"), a biotechnology company working to commercialize its patent-pending DNA gene sequencing artificial intelligence technology, announced today an update to shareholders regarding technology and marketing advancements. Frelii's CEO, Ian Jenkins stated, "Over the past year, through the diligence of our development team, led by respected industry...

Read more
ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer
BiotechnologyCompany Update

ReShape Lifesciences Appoints Thomas Stankovich as Chief Financial Officer

October 30, 2019 8:00 AM

SAN CLEMENTE, CA / ACCESSWIRE / October 30, 2019 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, announced today the appointment of Thomas Stankovich as Chief Financial Officer (CFO) effective immediately. "We are happy to have Tom join our senior leadership team as CFO," commented Bart Bandy, President and Chief Executive Officer of...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?